Compare CLAR & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLAR | NTHI |
|---|---|---|
| Founded | 1957 | 2008 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.9M | 114.6M |
| IPO Year | 1998 | N/A |
| Metric | CLAR | NTHI |
|---|---|---|
| Price | $3.36 | $3.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.08 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 413.3K | 88.7K |
| Earning Date | 05-07-2026 | 05-19-2026 |
| Dividend Yield | ★ 3.80% | N/A |
| EPS Growth | ★ 11.68 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $228,000.00 | N/A |
| Revenue This Year | $5.27 | N/A |
| Revenue Next Year | $3.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.53 | $3.01 |
| 52 Week High | $4.03 | $12.99 |
| Indicator | CLAR | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 60.76 | 29.70 |
| Support Level | $3.28 | N/A |
| Resistance Level | $3.53 | $5.78 |
| Average True Range (ATR) | 0.10 | 0.36 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 72.86 | 17.35 |
Clarus Corp is a designer, developer, manufacturer, and distributor of outdoor equipment and lifestyle products focused on the climb, ski, mountain, sport, and skincare markets. The company operates through the Outdoor segment, which includes Black Diamond Equipment and PIEPS, is a world-wide leader in designing, manufacturing, and marketing outdoor engineered equipment and apparel for climbing, mountaineering, trail running, backpacking, skiing, and a wide range of other year-round outdoor recreation activities. The Adventure segment, which includes Rhino-Rack, MAXTRAX and TRED, is a manufacturer of engineered automotive roof racks, trays, mounting systems, luggage boxes, carriers, recovery boards and accessories in Australia and New Zealand and U.S.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.